MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/liv.70163

Медицинская библиотека · Liver international : official journal of the International Association for the Study of the Liver · 2025

Targeting the Liver Serine Protease TMPRSS6 Ameliorates Steatosis and Attenuates Fibrosis in Experimental MASLD.

Pettinato Mariateresa, Furiosi Valeria, Carleo Rossana, Bavuso Volpe Letizia, Guo Shuling, Mannella Valeria, Musco Giovanna, Gilberti Enrica, De Palma Giuseppe, Federico Giorgia, Carlomagno Francesca, Cherubini Alessandro, Pelusi Serena, Dano Anxhela, Nai Antonella, Valenti Luca, Altamura Sandro, Pagani Alessia, Silvestri Laura

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of liver disease and a leading contributor to liver-related morbidity and mortality. Currently, no pharmacological approach has demonstrated consistent and long-lasting benefits across all patients. Therefore, identifying new therapeutic targets remains an urgent clinical need. The hepatic serine protease matriptase-2, encoded by TMPRSS6, inhibits the BMP-SMAD pathway. Interestingly, reduced BMP-SMAD signalling in the liver is frequently associated with altered lipid metabolism in patients. Conversely, inactivation of Tmprss6 has been linked to reduced high-fat diet-induced obesity. Based on these findings, we hypothesize that TMPRSS6 represents a novel and promising target for the treatment of MASLD.

METHODS

Hepatic TMPRSS6 expression was analysed in obese patients with or without MASLD. Adult male mice were fed a MASLD-MASH diet, and once hepatosteatosis was established, they were treated with antisense oligonucleotides targeting Tmprss6 while continuing the dietary regimen for an additional 6 weeks.

RESULTS

The expression of the BMP-SMAD inhibitor TMPRSS6 was increased in people with MASLD and negatively correlated with PPARα signaling, a key regulator of hepatic lipid metabolism. In experimental MASLD, downregulation of hepatocytic Tmprss6 using GalNAc-ASO significantly reduced steatohepatitis and fibrosis and attenuated MASLD-MASH-associated ferroptosis by reshaping hepatic transcription factor activity towards PPARα and SMAD4/SMAD5-driven signalling. Consistently, enhanced BMP-SMAD signalling increased PPARα activity in vivo.

CONCLUSIONS

Our findings reveal a novel functional crosstalk between TMPRSS6 and PPARα. Pharmacological downregulation of Tmprss6 in experimental MASLD mitigates hepatosteatosis, inflammation and fibrosis by enhancing PPARα signalling and attenuating ferroptosis.

Для цитирования: Pettinato Mariateresa, Furiosi Valeria, Carleo Rossana, Bavuso Volpe Letizia, Guo Shuling, Mannella Valeria, Musco Giovanna, Gilberti Enrica, De Palma Giuseppe, Federico Giorgia, Carlomagno Francesca, Cherubini Alessandro, Pelusi Serena, Dano Anxhela, Nai Antonella, Valenti Luca, Altamura Sandro, Pagani Alessia, Silvestri Laura. Targeting the Liver Serine Protease TMPRSS6 Ameliorates Steatosis and Attenuates Fibrosis in Experimental MASLD.. Liver international : official journal of the International Association for the Study of the Liver. 2025. DOI: 10.1111/liv.70163.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.